Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2019

View Archived Issues

Soricimed provides update on its PDC program, including in vivo data for SBI-1301

OAT-1746, a novel arginase inhibitor, reduces tumor growth in murine glioma models

Allopregnanolone affects metabolic and lipid pathways in Alzheimer's disease

BARDA exercises option to support Qpex product development

BioMarin reports encouraging final phase III data for vosoritide in children with achondroplasia

FDA removes partial clinical hold for multiple-ascending-dose study of RGLS-4326

Health Canada approves Erleada for the treatment of mCSPC

First patient enrolled in pivotal phase III InnovAATe study of Kamada's inhaled AAT

Sanofi presents data from phase I repeat-dosing study of BIVV-001

Pharmacokinetic and antidrug antibody status of ABP-959 biosimilar compared to eculizumab

Phase Ib results for PVX-410 vaccine in combination with durvalumab in TNBC

SM-08502 demonstrates promising activity in TNBC models

Macrophage activity backfires in S. aureus infection

Phase III GEMINI study of AXS-05 in MDD achieves primary endpoint

BeiGene presents cohort 1 results of ASPEN study of zanubrutinib in Waldenstrom's macroglobulinemia

Amgen discloses new KRAS G12C inhibitors

TAM receptor family tyrosine kinase inhibitors patented by Rigel Pharmaceuticals

VenatoRx Pharmaceuticals identifies new carbapenems

Merck & Co. presents new IDO-1 inhibitors

New HIV integrase inhibitors identified at Shionogi

[18F]GTP-1 imaging shown to be useful to detect cognitive decline

Study shows causal link between elevated activity of type 1 interferon and human disease

Tonix to advance development of TNX-601 CR for depression and PTSD

Medivir ends phase II colorectal cancer study of birinapant with pembrolizumab for futility

FDA approves Xtandi for metastatic castration-sensitive prostate cancer

Antisense Therapeutics plans to advance ATL-1102 into phase IIb for DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...